These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 11885411)

  • 1. Management challenge with drotrecogin alfa (activated).
    Vanscoy GJ
    Am J Health Syst Pharm; 2002 Feb; 59 Suppl 1():S23-9. PubMed ID: 11885411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.
    Angus DC; Linde-Zwirble WT; Clermont G; Ball DE; Basson BR; Ely EW; Laterre PF; Vincent JL; Bernard G; van Hout B;
    Crit Care Med; 2003 Jan; 31(1):1-11. PubMed ID: 12544986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost-effectiveness of drotrecogin alpha [activated] in the treatment of severe sepsis in Spain].
    Sacristán JA; Prieto L; Huete T; Artigas A; Badia X; Chinn C; Hudson P
    Gac Sanit; 2004; 18(1):50-7. PubMed ID: 14980173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures.
    Betancourt M; McKinnon PS; Massanari RM; Kanji S; Bach D; Devlin JW
    Pharmacoeconomics; 2003; 21(18):1331-40. PubMed ID: 14750900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
    Davies A; Ridley S; Hutton J; Chinn C; Barber B; Angus DC
    Anaesthesia; 2005 Feb; 60(2):155-62. PubMed ID: 15644013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany.
    Neilson AR; Burchardi H; Chinn C; Clouth J; Schneider H; Angus D
    J Crit Care; 2003 Dec; 18(4):217-27. PubMed ID: 14691895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drotrecogin alfa (activated) approved for treatment of severe sepsis.
    Poe K
    J Am Pharm Assoc (Wash); 2002; 42(3):520-2. PubMed ID: 12030642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drotrecogin alfa: a role in emergency department treatment of severe sepsis?
    McLeay AM
    Emerg Med Australas; 2004 Aug; 16(4):324-35. PubMed ID: 15283720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drotrecogin alfa (activated) for severe sepsis.
    Drug Ther Bull; 2006 Jan; 44(1):5-8. PubMed ID: 16425899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meeting unmet needs in patients with sepsis: the role of drotrecogin alfa (activated).
    Morris PE
    Am J Crit Care; 2003 Mar; 12(2):94-7. PubMed ID: 12625165
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of drotrecogin alfa (activated) in older patients with severe sepsis.
    Alexander SL; Ernst FR
    Pharmacotherapy; 2006 Apr; 26(4):533-8. PubMed ID: 16553513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical response to unintentionally rapid infusion of drotrecogin alfa (activated).
    Urban TM; Mitchell GA; Wellborn-Kim JJ; Terneus WF; Callahan CM; Mendes J; Webber SL
    Am J Health Syst Pharm; 2010 Jul; 67(14):1174-7. PubMed ID: 20592322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meeting unmet needs in patients with sepsis: the role of drotrecogin alfa (activated).
    McEvoy M
    Am J Crit Care; 2003 Sep; 12(5):398; author reply 398. PubMed ID: 14503421
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
    Green C; Dinnes J; Takeda AL; Cuthbertson BH
    Int J Technol Assess Health Care; 2006; 22(1):90-100. PubMed ID: 16673685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.
    Ely EW; Laterre PF; Angus DC; Helterbrand JD; Levy H; Dhainaut JF; Vincent JL; Macias WL; Bernard GR;
    Crit Care Med; 2003 Jan; 31(1):12-9. PubMed ID: 12544987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-based disease management in medication-use evaluation: application to drotrecogin alfa (activated) in severe sepsis.
    Durthaler JM; Ernst FR
    Am J Health Syst Pharm; 2006 Aug; 63(15):1453-60. PubMed ID: 16849712
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.
    Green C; Dinnes J; Takeda A; Shepherd J; Hartwell D; Cave C; Payne E; Cuthbertson BH
    Health Technol Assess; 2005 Mar; 9(11):1-126, iii-iv. PubMed ID: 15774234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of drotrecogin alfa (activated) on resource use and implications for reimbursement.
    Dasta JF; Cooper LM
    Pharmacotherapy; 2002 Dec; 22(12 Pt 2):216S-222S. PubMed ID: 12492228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drotrecogin alfa (activated) in South African private hospital ICUs.
    Hodgson RE; Williams PG; Foden AP; Grolman D
    S Afr Med J; 2003 Jul; 93(7):474-5. PubMed ID: 12939910
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.
    Bernard GR; Macias WL; Joyce DE; Williams MD; Bailey J; Vincent JL
    Crit Care; 2003 Apr; 7(2):155-63. PubMed ID: 12720562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.